BioStock: RhoVac gives update on phase IIb results and presents action plan

Just over a month ago, Lundbased Rhovac reported topline results from the phase IIb study with the drug candidate onilcamotide, where unfortunately they did not see the hoped-for effect. After taking a closer look at the results, the company has given another update and presented some possible ways forward. BioStock contacted RhoVac’s CEO Anders Månsson to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/rhovac-gives-update-on-phase-iib-results-and-presents-action-plan/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se